Biohaven advances development of its extracellular target degrader platform technology (MoDEs™) for therapies across a variety of diseases including.
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Knopp Biosciences and Population Health Partners Create Areteia Therapeutics, New Clinical-Stage Asthma Company, with $350 Million in Funding - read this article along with other careers information, tips and advice on BioSpace
/PRNewswire/ Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") announced today that it has entered into a definitive.
Biohaven Enrolls Phase 1a/1b Clinical Trial of BHV-1100, Lead Asset from its ARM™ (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma - read this article along with other careers information, tips and advice on BioSpace